2020 American Transplant Congress
Differences in Alemtuzumab Dosing Does Not Affect Early Kidney Transplant Outcomes
Wake Forest Baptist Health, Winston-Salem, NC
*Purpose: Alemtuzumab (Alem) is a widely used medication for induction therapy in kidney transplantation. However, there is limited evidence comparing outcomes with low versus high…2020 American Transplant Congress
Causal Relationship between Anti-Thymocyte Globulin Induction Therapy and Development of Monomorphic PTLD in Renal Transplant Recipients
*Purpose: The aim of our study is to explore the causality between ATG and different types of post-transplant lymphoproliferative disorder (PTLD) in renal transplant recipients…2020 American Transplant Congress
Maintenance Steroids in the Setting of Alemtuzumab Induction Post-Kidney Transplant Increases Risk of Infection and Hospital Readmission
Tampa General Hospital, Tampa, FL
*Purpose: This study sought to assess the safety of steroid-containing maintenance immunosuppression in the setting of alemtuzumab (ALEM) induction.*Methods: Adult (>18 years) kidney transplant recipients…2020 American Transplant Congress
Thymoglobulin Induction in Kidney Transplant Recipients: A Single Center Experience Comparing 3 Mg/kg vs 5 Mg/kg Cumulative Dosing
*Purpose: Beginning in 2016, our center implemented a protocol change to thymoglobulin (r-ATG) induction dosing in kidney transplant recipients at low rejection risk from 5…2020 American Transplant Congress
Single Center Experience Using Low-Dose Antithymocycte Globulin for Induction Following Heart Transplant
Wake Forest Baptist Health System, Winston Salem, NC
*Purpose: The use of induction therapy after cardiac transplantation remains highly variable, not only in terms of which agent is used, but whether it is…2020 American Transplant Congress
Navigating Through IgM Antibodies in Deceased Donor Kidney Transplants from A2/A2B Donors to B Recipients
University of Texas Medical Branch, Galveston, TX
*Purpose: Multiple studies have shown acceptable deceased donor transplant (DDT) outcomes from A2 and A2B donors into B recipients; however, concerns remain for acute rejection…2020 American Transplant Congress
Short Term Outcomes in Kidney Transplant Patients Receiving De Novo Belatacept with Anti-Thymocyte Globulin Induction
Pharmacy, Jackson Memorial Hospital, Miami, FL
*Purpose: Mainstay immunosuppressive therapy after kidney transplant is a calcineurin inhibitor (CNI) based regimen. Nephrotoxicity is a common adverse effect of CNIs which can lead…2020 American Transplant Congress
Peri-Operative Extracorporeal Photopheresis in High Risk Patients after Heart Transplantation
*Purpose: Extracorporeal photopheresis (ECP) is an established therapy for treatment of heart transplant rejection and is also applied for rejection prevention in the perioperative setting…2020 American Transplant Congress
Anti-HLA IgM Antibodies are Unaffected by Imlifidase (IdeS) Treatment
*Purpose: The immunoglobulin G (IgG)-degrading cysteine protease, imlifidase (IdeS) is an IgG endopeptidase under development as a rapid desensitization treatment in kidney transplantation. Imlifidase is…2020 American Transplant Congress
Outcomes of Induction with T Lymphocyte-Depleting and IL-2 Receptor Blocking (IL-2RB) Antibodies in the Non-Broadly Sensitized Adult Deceased-Donor Kidney Transplant Recipients: Analysis in the Context of the CPRA Allocation System
*Purpose: We studied outcomes of induction in non-broadly-sensitized adult deceased-donor kidney transplant recipients(DD-KTRs) in the context of the calculated panel reactive antibody (CPRA) allocation system.*Methods:…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 27
- Next Page »